Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial-Reference-Cited by-同舟云学术

Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial

Published:2019-03-12 Issue:12 Volume:25 Page:3581-3588
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Rothé Françoise,Silva Maria Joao,Venet David,Campbell Christine,Bradburry Ian,Rouas Ghizlane,de Azambuja Evandro,Maetens Marion,Fumagalli Debora,Rodrik-Outmezguine Vanessa,Di Cosimo Serena,Rosa Daniela,Chia Stephen,Wardley Andrew,Ueno Takayuki,Janni Wolfgang,Huober Jens,Baselga Jose,Piccart Martine,Loi Sherene,Sotiriou Christos,Dawson Sarah-Jane,Ignatiadis Michail

Funder

National Breast Cancer FoundationNational Breast Cancer Foundation (NBCF)

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early evaluation of circulating tumor DNA as marker of therapeutic efficacy and prognosis in breast cancer patients during primary systemic therapy;The Breast;2024-08

2. Modeling the management of patients with human epidermal growth factor receptor 2-positive breast cancer with liquid biopsy: the future of precision medicine;Current Opinion in Oncology;2024-07-16

3. Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer?;Expert Review of Anticancer Therapy;2024-07

4. Use of ctDNA in early breast cancer: analytical validity and clinical potential;npj Breast Cancer;2024-06-19

5. Clinical applications of next‐generation sequencing‐based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression;Molecular Oncology;2024-06-12